NeurologyHow biotech is treating epilepsy beyond seizuresFor decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and … more ➔
TecanLab automationThe emergence of agentic AI in lab automationThere’s uncertainty and concern about whether AI will replace humans in workplaces. But Marco Ravot-Licheri, Head of Digital – Life Sciences Business at Tecan, told us that AI could increase laboratory … more ➔
RegulatoryFast-track trial approval: a way to jump the EU queue?Launched in 2022, the EU Clinical Trials Information System (CTIS) aims to streamline and centralise the process of applying for clinical trial authorisation, but has also increased typical approval … more ➔
TechnologiesRNA medicine enters its second actThe COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing … more ➔
Bayer AGBayerBayer rebuilds pharma while waiting for Monsanto reliefA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation. more ➔
Wuxi AppTecChinaWuXi AppTec bets on expansion in EuropeGlobal science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues … more ➔
TechnologyTargeted Protein Degradation: Designed to destroyTargeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting … more ➔
Watchlist8 European VC firms to watch in 2026European biotech enters 2026 in a strange, almost contradictory mood. The easy-money years are gone, the post-pandemic correction has done its damage, and investors are no longer rewarding science … more ➔
M&ACan Sanofi buy its way into in vivo CAR-T?Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from … more ➔
WhiteLab GenomicsInterviewAI: Breaking barriers in CNS researchDelivering therapeutic genetic material safely to the correct target in the body is one of the big challenges of modern medicine. We talked to David Del Bourgo, CEO of WhiteLab Genomics, about how AI … more ➔
Tecan
Bayer AG
Wuxi AppTec
WhiteLab Genomics